Lupin (company)
Tracked across 13 events · 221 articles · First seen Mar 20, 2025 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Lupin (company) entered a licensing and supply agreement with Astec LifeSciences to co-market Semaglutide Injection in India, gaining semi-exclusive rights to distribute the drug under its own brand names. This enhances its diabetes portfolio and strengthens its commitment to advanced cardio-metabolic treatments.
Mar 17, 2026 · 7 articles
Business
Impact: Lupin (company) completed the acquisition of VISUfarma, significantly expanding its ophthalmology portfolio and strengthening its presence in Europe. This acquisition is expected to be immediately accretive and accelerate its specialty franchise build-out.
Apr 02, 2026 · 13 articles
Regulatory
Impact: Lupin (company) received tentative approval from the U.S. FDA for its Enzalutamide Tablets, which is a positive development for the company as it expands its product offerings and market reach.
Jun 26, 2026 · 16 articles
Business
Impact: Lupin (company) was recognized as one of the World's Most Sustainable Companies by TIME and Statista, highlighting its strong ESG performance and commitment to sustainability.
Jul 06, 2026 · 6 articles
Regulatory
Impact: Lupin (company) is the manufacturer of the recalled eye drops; the recall may harm its brand and lead to potential liability, though the company is cooperating voluntarily.
Jul 07, 2026 · 38 articles
Business
Impact: Lupin spins out two oncology assets to Kaveri, retaining significant equity and providing seed funding, which may streamline its pipeline and create value.
Jul 21, 2026 · 7 articles
Regulatory
Lupin (company) announced on August 17, 2026, that it received final approval from the U.S. United States — Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg…
Impact: Lupin received FDA approval for its generic Pitolisant tablets, which is a positive development for its U.S. business and may lead to increased sales and market share.
Aug 17, 2026 · 6 articles
Business
Lupin (company)'s wholly-owned subsidiary VISUfarma has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a wholly-owned subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI, a once-daily eye drop for presbyopia, in the…
Impact: Lupin, through its subsidiary VISUfarma, secures exclusive rights to commercialize YUVEZZI in key European Union — European markets, strengthening its ophthalmology franchise and specialty care strategy. The deal includes a strategic investment and potential milestone payments, which could enhance future revenue.
Aug 20, 2026 · 12 articles
Business
Impact: Lupin (company), in partnership with Natco Pharma, received U.S. FDA approval for Eribulin Mesylate Injection, which is expected to provide a competitive edge in the oncology market and contribute to its sales.
Jun 03, 2026 · 8 articles
Business
Impact: Lupin (company) is preparing to roll out generic semaglutide and has formed a licensing partnership with Astec LifeSciences, aiming to compete in the Indian weight-loss drug market.
Mar 20, 2026 · 8 articles
Business
Impact: Lupin's insulin glargine products face increased competition from Awiqli.
Jul 09, 2026 · 21 articles
Regulatory
Impact: Lupin is a major generic drug supplier to the US; the tariff plan poses a risk to its US market share.
Jul 21, 2026 · 73 articles
Business
Impact: Lupin was in early-stage discussions to acquire Vitabiotics but did not proceed.
Jul 24, 2026 · 6 articles
90
Lupin (company) entered licensing agreement Visus Therapeutics Inc.Lupin VISUfarma licenses...
ERGEN INTELLIGENCE
Track Lupin (company) live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard